Patents by Inventor Yohei Yuki
Yohei Yuki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240376109Abstract: Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]: wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.Type: ApplicationFiled: June 1, 2022Publication date: November 14, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yukitaka UEMATSU, Minoru OKADA, Akihiro SAITO, Akira TAKAHASHI, Yuichi NAKAMURA, Taiki HANARI, Yasuhiro MENJO, Takahito YAMAUCHI, Atsushi YAMAGUCHI, Yohei YUKI, Kenji WATANABE, Satoshi MATSUDA
-
Publication number: 20240366573Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: ApplicationFiled: July 16, 2024Publication date: November 7, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
-
Publication number: 20220117944Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: ApplicationFiled: January 3, 2022Publication date: April 21, 2022Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
-
Publication number: 20200171006Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: ApplicationFiled: February 5, 2020Publication date: June 4, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
-
Patent number: 10588893Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: GrantFiled: December 27, 2016Date of Patent: March 17, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro Murakami, Hitoshi Matsushita, Kengo Matsumoto, Minoru Okada, Yohei Yuki, Noriyuki Koyama, Naohiko Kanai
-
Publication number: 20190000810Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.Type: ApplicationFiled: December 27, 2016Publication date: January 3, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
-
Patent number: 9708292Abstract: The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.Type: GrantFiled: February 2, 2010Date of Patent: July 18, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Norifumi Sato, Yohei Yuki, Hisashi Shinohara, Yasuhiro Takeji, Kuni Ito, Daisaku Michikami, Keisuke Hino, Hiroyuki Yamazaki
-
Patent number: 8906852Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.Type: GrantFiled: April 8, 2011Date of Patent: December 9, 2014Assignee: MethylGene Inc.Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Publication number: 20140315801Abstract: This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling.Type: ApplicationFiled: June 18, 2014Publication date: October 23, 2014Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frederic Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Publication number: 20120022077Abstract: The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.Type: ApplicationFiled: February 2, 2010Publication date: January 26, 2012Inventors: Norifumi Sato, Yohei Yuki, Hisashi Shinohara, Yasuhiro Takeji, Kuni Ito, Daisaku Michikami, Keisuke Hino, Hiroyuki Yamazaki
-
Publication number: 20110257100Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.Type: ApplicationFiled: April 8, 2011Publication date: October 20, 2011Inventors: Stëphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frëdëric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Patent number: 7700618Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asType: GrantFiled: February 23, 2007Date of Patent: April 20, 2010Assignee: Pfizer IncInventors: Tomoki Kato, Kana Kon-I, Yohei Yuki, Kazuo Ando
-
Publication number: 20090137584Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asType: ApplicationFiled: February 23, 2007Publication date: May 28, 2009Inventors: Tomoki Kato, Kana Kon-I, Yohei Yuki, Kazuo Ando